Innate Pharma SA Files 6-K Report

Ticker: IPHYF · Form: 6-K · Filed: Sep 5, 2024 · CIK: 1598599

Innate Pharma SA 6-K Filing Summary
FieldDetail
CompanyInnate Pharma SA (IPHYF)
Form Type6-K
Filed DateSep 5, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: 6-K, foreign-private-issuer, filing-update

TL;DR

Innate Pharma SA filed a 6-K on 9/5/24, standard foreign issuer update.

AI Summary

On September 5, 2024, Innate Pharma SA filed a Form 6-K, reporting its status as a foreign private issuer. The filing confirms the company's principal executive office is located at 117 Avenue de Luminy, Marseille, France. Innate Pharma SA is registered with the SEC under file number 001-39084 and operates in the biological products sector.

Why It Matters

This filing is a routine disclosure for foreign private issuers, providing an update on the company's administrative and reporting status to the SEC.

Risk Assessment

Risk Level: low — This is a routine administrative filing for a foreign private issuer and does not contain new financial or operational information.

Key Players & Entities

  • Innate Pharma SA (company) — Registrant
  • 001-39084 (company) — SEC File Number
  • September 5, 2024 (date) — Filing Date
  • 117 Avenue de Luminy, Marseille, France (location) — Principal Executive Office

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer makes or is required to make public in its home country.

What is Innate Pharma SA's SEC file number?

Innate Pharma SA's SEC file number is 001-39084.

Where is Innate Pharma SA's principal executive office located?

Innate Pharma SA's principal executive office is located at 117 Avenue de Luminy, BP 30191, 13009 Marseille, France.

What is the SIC code for Innate Pharma SA?

The Standard Industrial Classification (SIC) code for Innate Pharma SA is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Does Innate Pharma SA file annual reports under Form 20-F?

Yes, Innate Pharma SA indicates it files annual reports under cover of Form 20-F.

Filing Stats: 206 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2024-09-05 06:10:23

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date September 5, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.